OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
🇺🇸United States
Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation
Phase 1
Terminated
- Conditions
- Atrial FibrillationParoxysmal Atrial FibrillationPersistent Atrial Fibrillation
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2017-04-10
- Target Recruit Count
- 40
- Registration Number
- NCT01483183
- Locations
- 🇬🇧
Otsuka Investigational Site, Chertsey, Surrey, United Kingdom
8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase 2
Completed
- Conditions
- Autosomal Dominant Polycystic Kidney Disease
- Interventions
- First Posted Date
- 2011-10-14
- Last Posted Date
- 2018-09-27
- Target Recruit Count
- 178
- Registration Number
- NCT01451827
- Locations
- 🇺🇸
Otsuka Investigational Site, Charlottesville, Virginia, United States
🇺🇸Otsuka Investigational Site 2, Aurora, Colorado, United States
Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder
- First Posted Date
- 2011-10-06
- Last Posted Date
- 2015-11-06
- Target Recruit Count
- 1036
- Registration Number
- NCT01447576
- Locations
- 🇺🇸
Artemis Institute for Clinical Research, San Diego, California, United States
🇺🇸Goldpoint Clinical Research, LLC, Indianapolis, Indiana, United States
🇺🇸Oregon Center for Clinical Investigations, Inc., Portland, Oregon, United States
Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type
Phase 3
Completed
- Conditions
- Dementia, Alzheimer Type
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-09-21
- Last Posted Date
- 2013-12-02
- Target Recruit Count
- 232
- Registration Number
- NCT01438060
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
Phase 3
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2011-09-13
- Last Posted Date
- 2015-05-07
- Target Recruit Count
- 493
- Registration Number
- NCT01432444
Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease
Completed
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- First Posted Date
- 2011-09-08
- Last Posted Date
- 2015-04-23
- Target Recruit Count
- 3409
- Registration Number
- NCT01430494
- Locations
- 🇺🇸
Otsuka Investigational Site 2, Peoria, Arizona, United States
🇫🇷Otuska Investigational Site, Lyon cedex 3, France
🇬🇧Otsuka Investigational Site, Wolverhampton, United Kingdom
Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis
Phase 3
Completed
- Conditions
- Multidrug-resistant Tuberculosis
- Interventions
- Drug: Placebo + OBR
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2019-05-15
- Target Recruit Count
- 511
- Registration Number
- NCT01424670
Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder
Phase 1
Completed
- Conditions
- SchizophreniaSchizoaffective Disorder
- Interventions
- First Posted Date
- 2011-08-26
- Last Posted Date
- 2015-10-29
- Target Recruit Count
- 218
- Registration Number
- NCT01423916
- Locations
- 🇺🇸
Otsuka Investigational Site, Austin, Texas, United States
Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer
- First Posted Date
- 2011-08-26
- Last Posted Date
- 2014-01-15
- Target Recruit Count
- 45
- Registration Number
- NCT01423903
Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)
- First Posted Date
- 2011-08-17
- Last Posted Date
- 2021-10-07
- Target Recruit Count
- 83
- Registration Number
- NCT01418352
© Copyright 2025. All Rights Reserved by MedPath